A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer

Abstract

In this national analysis, wedge resection was associated with better survival for stage IA non-small cell lung cancer than stereotactic body radiotherapy.

All evidence points to the need for collaborative care

“…These letters 1,2 highlight the need for collaborative care from thoracic surgeons and radiation oncologists for patients with early stage NSCLC. As discussed in our article, 3 we agree that our patients with NSCLC of all stages will best be cared for through multidisciplinary management to guide the best treatment plan for each individual patient. The evolution of NSCLC treatment with the identification of actionable mutations and the development of new therapies has made multidisciplinary care of our patients more important than ever.…”

“…A limitation of our comparative analysis of sublobar resection versus stereotactic body radiation therapy (SBRT) for patients with early stage lung cancer that was highlighted in our article 3 is the lack of pulmonary function tests. Because of the observational nature of our analysis, we recognize that not knowing specific patient comorbidities and pulmonary function test values confound the comparison, and we were and continue to be careful regarding the results and conclusions drawn from the study.…”

Surgery versus stereotactic body radiation therapy for stage I non–small cell lung cancer: A comprehensive review

“…A number of studies have used large national cancer databases to compare outcomes of surgery and SBRT for early‐stage NSCLC. Using the National Cancer Data Base, Yerokun et al showed improved overall survival with wedge resection versus SBRT (50% vs 31%; P < .001) in a propensity score–matched analysis. Using the Surveillance, Epidemiology, and End Results–Medicare linked database, Yu et al performed a propensity‐matched analysis evaluating patients 67 years old or older.…”

Современные Тенденции Использования Лучевой Терапии В Лечении Местнораспространенных (IIIA / N2 Стадия) И Ранних Форм (I–II Стадия) Немелкоклеточного Рака Легкого, Или Роль Лучевой Терапии В Лечении Немелкоклеточного Рака Легкого На Современном Этапе

“…Активное внедрение в последние годы во многих странах скрининговых программ позволяет надеяться на существенное увеличение доли пациентов с ранними формами НМРЛ [37,45]. Хирургическое лечение, явля-ющееся стандартом при локализованном НМРЛ, в связи с функциональными ограничениями может быть выпол-нено только у 65-70 % больных, а у пациентов старше 75 лет их доля не превышает 50 %.…”